Tarik Möröy

Biography

Tarik Möröy is the fourth president and permanent scientific director of the Montreal Institute of Clinical Research. Dr. Möröy is also Director of the Hematopoiesis and Cancer Research Unit and Canada Research Chair (Level 1) in hematopoiesis and differentiation of immune cells. To date, Dr. Möröy’s list of publications includes more than 300 titles, including 127 original articles published in peer-reviewed journals, 26 journal articles and book chapters, and over 130 abstracts presented at congresses and symposia. Tarik Möröy holds a Ph.D. (1987) in Biochemistry from the University of Ludwig-Maximilians in Munich, Germany. He did the practical work for his doctoral thesis at the Institut Pasteur in Paris (1984-1987), and worked as a postdoctoral researcher at Columbia University in New York (1988-1991). In 1991, Dr. Möröy returned to Germany to become an independent junior team leader (the equivalent of assistant professor) at the Philipps University Marburg Institute for Molekular Biology and Tumorforschung. At this University, he also passed an empowerment thesis to lead research in molecular biology and immunology (1994). In 1995 he was appointed associate professor and in 1996 he became full professor of cellular and molecular biology at the Faculty of Medicine of the Duisburg-Essen University. At this University, he worked as a professor and principal investigator at the Institute of Cell Biology (Institut für Zellbiologie, IFZ). Dr. Möröy also held administrative positions at the University of Duisburg-Essen as Executive Director of the Institute for Cell Biology (Institut für Zellbiologie, IFZ) (1996-1999 and 2002-2005) and Chairman of the Executive Board of the Biotechnology Center Medical (ZMB, 2003-2005).

Team

Themes

• Molecular Biology and immunology
• Molecular hematology

Research topics

• Mechanisms of differentiation of immune cells
• Transcription and epigenetic factors
• Leukemia and lymphoma
• Alternative splicing in immune cells

Selected publications (6)

• Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, Orthwein A, Drobetsky E and Möröy T. GFI1 is required for efficient DNA Repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1. Nature Communications, 2018, Apr 12;9(1):1418.
• Gaudreau MC, Grapton D, Helness A, Vadnais C, Fraszczak J, Shooshtarizadeh P, Wilhelm B, Robert F, Heyd F, Möröy T. Heterogeneous Nuclear Ribonucleoprotein L is required for the survival and functional integrity of murine hematopoietic stem cells. Reports, 2016, June 7; 6: 27379
• Rashkovan M, Vadnais C, Ross J, Gigoux M, Suh WK, Gu W and Möröy T. Miz-1 regulates translation of Trp53 via ribosomal protein L22 in cells undergoing V(D)J recombination. Natl. Acad. Scie. (USA), 2014, Dec 16;111(50):E5411-9.
• Preußner M, Wilhelmi I, Schultz AS, Finkernagel F, Michel M, Möröy T, Heyd F. Rhythmic U2af26 alternative splicing controls PERIOD1 stability and the circadian clock in mice. Mol Cell, 2014 May 22;54(4):651-62.
• Khandanpour C, Phelan JD, Vassen L, Schütte J, Chen R, Horman SR, Gaudreau MC, Krongold J, Zhu J, Paul WE, Dührsen U, Göttgens B, Grimes HL, Möröy T. Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. Cancer Cell, 2013 Feb 11;23(2):200-14.
• Kosan C, Saba I, Godmann M, Herold S, Herkert B, Eilers M, Möröy T. Transcription factor miz-1 is required to regulate interleukin-7 receptor signaling at early commitment stages of B cell differentiation. Immunity, 2010 Dec 14;33(6):917-28.